Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
Recruiting
Background: Severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS) are bone marrow diseases. People with these diseases usually need a bone marrow transplant. Researchers are testing ways to make stem cell transplant safer and more effective. Objective: To test if treating people with SAA or MDS with a co-infusion of blood stem cells from a family member and cord blood stem cells from an unrelated donor is safe and effective. Eligibility: Recipients ages 4-60 with SAA or MDS Donor... Read More
Gender:
ALL
Ages:
Between 4 years and 75 years
Trial Updated:
05/01/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Severe Aplastic Anemia, Hypo-Plastic MDS, Myelodysplastic Syndrome (MDS)
Anatomical and Functional Imaging Correlates of Chronic Pain in Cerebral Palsy
Recruiting
The investigators hope to use MRI biomarkers to identify and characterize sensorimotor network disruption patterns associated with chronic pain and sensory deficits in CP. Investigators will use existing information in the medical record as well as subjective reports from interview, physical exam data, and anatomical and functional MRI data to non-invasively identify brain injury correlates of pain and sensory deficits.
Gender:
ALL
Ages:
8 years and above
Trial Updated:
05/01/2025
Locations: F.M. Kirby Center, Baltimore, Maryland +3 locations
Conditions: Cerebral Palsy, Chronic Pain
Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation
Recruiting
To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/01/2025
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
Conditions: Hematopoietic Stem Cell Transplant
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Recruiting
Background: High-grade neuroendocrine carcinomas (HGNEC) are cancers that develop in different parts of the body, including the digestive tract, genitals, neck, and head. One drug (belinostat), combined with 2 other drugs (etoposide and cisplatin), is approved to treat HGNEC. But some people may have a gene variant that affects how quickly their body gets rid of the drug; these people may do better with different dosages of belinostat. Objective: To test higher or lower doses of belinostat ba... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/01/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Carcinoma, Neuroendocrine, Tumor, Neuroendocrine, Tumors, Neuroendocrine, Neuroendocrine; Carcinoma, Small Cell; Receptors
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
Recruiting
The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects. We expect that DMT will induce changes in neuroplasticity as indexed using electroencephalographic (EEG) measures and tasks in both depressed individuals and healthy volunteers, though to differe... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
05/01/2025
Locations: Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West Haven, Connecticut
Conditions: Major Depression Disorder, Depression
Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder
Recruiting
Background: People with addictions often find it hard to choose the long-term benefits of abstinence over the short-term effects of using drugs. Researchers think this is partly due to parts of the brain involved in certain types of learning and decision-making. Researchers want to test these basic functions using a simple task with pictures and odors. Objective: To see if performance in a learning task differs between people who have opioid-use disorder and people who don t. Eligibility: A... Read More
Gender:
ALL
Ages:
Between 21 years and 60 years
Trial Updated:
05/01/2025
Locations: National Institute on Drug Abuse, Baltimore, Maryland
Conditions: Drug Addiction, Opioid-Related Disorders
Caplyta in Borderline Personality Disorder
Recruiting
The primary objective of the proposed study is to evaluate the safety and efficacy of Caplyta (lumateperone) in adults with borderline personality disorder (BPD). Sixty subjects with BPD will be randomized in a 1:1 fashion to either Caplyta (42mg/day) or matching placebo for 8 weeks of active treatment. The hypothesis to be tested is that Caplyta will result in greater rates of reduction in symptoms of BPD compared to placebo (improvement in symptoms will be indicated by lower scores on establis... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/01/2025
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Borderline Personality Disorder
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
Recruiting
This is a Phase II study to determine the rate of stabilization or disease improvement from investigational decitabine/cedazuridine (INQOVI) treatment in subjects with BRCA1-Associated Protein-1 (BAP1) Cancer Predisposition Syndrome (CPDS) and subclinical, early-stage mesothelioma. Progression-free survival (PFS) will also be determined for treated subjects, and the treatment safety (toxicity) evaluated.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/01/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
Recruiting
Background: People with colorectal cancer (CRC) or gastroesophageal cancer (GEC) must often have major surgery to remove tumors from the esophagus, stomach, colon, or rectum. These surgeries can have adverse effects on their quality of life. Researchers want to know if one or two approved drugs (nivolumab with or without ipilimumab) can help people with CRC or GEC delay or avoid surgery. Objective: To test 1 or 2 drugs in people with CRC or GEC. Eligibility: People aged 18 years and older w... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
05/01/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Colorectal Cancer, Gastroesophageal Cancer
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
Recruiting
The primary objective of the study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP)
Gender:
ALL
Ages:
Between 3 months and 12 years
Trial Updated:
05/01/2025
Locations: Children's Hospital of Orange County, Orange, California +2 locations
Conditions: Acute Pyelonephritis, Complicated Urinary Tract Infection
Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis
Recruiting
Background: Atopic dermatitis (AD), also called eczema, makes skin dry, red, and itchy. People with AD are more likely to get a food allergy than people without AD. But some food allergy tests are not always accurate in people with AD. Researchers want to study if people are truly allergic to milk and/or peanuts. Objectives: To improve the ways doctors test for food allergy in people with AD. Eligibility: People ages 3 21 who have had AD; have a high total IgE level (an allergic antibody);... Read More
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
05/01/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Milk and/or Peanut Allergy
Neonatal Phase 1 Valacyclovir Study
Recruiting
A Phase 1 study that will determine the valacyclovir dose that results in a systemic acyclovir exposure comparable to 10 mg/kg of parenterally administered acyclovir, which is an AUC0-12 of 24,000 ngxhr/mL to 48,000 ngxhr/mL. Neonates at risk of acquiring neonatal HSV will be enrolled in one of 2 cohorts. Cohort 1 will be comprised of eight subjects who will receive an initial dose of 10ml/kg of oral valacyclovir. Samples for PK assessments will be obtained to assess the exposure concentration.... Read More
Gender:
ALL
Ages:
Between 1 day and 2 days
Trial Updated:
05/01/2025
Locations: Children's of Alabama Child Health Research Unit (CHRU), Birmingham, Alabama +11 locations
Conditions: Herpes Simplex